Dr. Chovatiya discusses a symposium that he participated in at AAD 2025 focused on chronic hand eczema, reviewing prevalence, subtypes, morphology, and other important considerations for optimizing the treatment of CHE.
Dr. Chovatiya discusses a symposium that he participated in at AAD 2025 focused on chronic hand eczema, reviewing prevalence, subtypes, morphology, and other important considerations for optimizing the treatment of CHE.
Dr. Lio discusses the complex relationship between diet and **Atopic Dermatitis (AD), addressing common patient questions, misconceptions, and concerns regarding dietary modifications. His presentation emphasizes
Dr. Graber reviews emerging evidence supporting the use of energy-based devices for the treatment of Acne Vulgaris and Rosacea, highlighting how advances in laser and
Dr. Daveluy discusses practical techniques and clinical considerations for using cryoinsufflation in the treatment of Hidradenitis Suppurativa (HS). His presentation provides guidance on incorporating this
Dr. Bunick examines the ongoing discussion surrounding benzene contamination concerns in benzoyl peroxide (BPO) products, addressing questions about product safety, regulatory oversight, and best practices
Dr. Lio discusses strategies for addressing chronic itch (pruritus) in patients undergoing treatment for non-dermatologic cancers, a symptom that can significantly affect comfort, sleep quality,
Dr. Daveluy explores the important relationship between nutrition and dermatologic therapies, discussing how dietary choices can influence the effectiveness, absorption, and side effect profiles of
Dr. Jennifer Hsiao shares emerging strategies for treating recalcitrant hidradenitis suppurativa when standard therapies fail. Topics Covered: Management of treatment-resistant HS Emerging therapies and clinical
Dr. Bunick provides a comprehensive update on using antibiotics for the treatment of acne and rosacea, including influences on gut health, antibiotic resistance, and efficacy
Dr. Swanson highlights key developments presented at the AAD 2025 Annual Meeting, providing an overview of emerging therapies, clinical research, and treatment advances across several
Dr. Hamzavi reviews the correct patient candidate for surgical therapy for vitiligo and the different options available, including punch grafting, suction blister epidermal grafting, and
Dr. Hamzavi discusses key points from his presentation within the AAD 2025 session on surgical options for hidradenitis suppurativa.
Dr. Rosmarin highlights his presentation from AAD 2025, in which he reviewed the optimal method for using ruxolitinib cream for vitiligo, touching on setting patient
In a summary of one of his talks from AAD 2025, Dr. Drucker discusses the results from a network meta-analysis that provides insight beyond the
Dr. Chovatiya reviews one of his AAD sessions in which he discussed atopic dermatitis, hidradenitis suppurativa, and psoriasis in patients with skin of color. In
Dr. Gooderham discusses JAK inhibition in the context of psoriasis treatment, including comparing the important difference between competitive inhibition and allosteric inhibition when using JAKs
In an overview from his AAD 2025 presentation, Dr. Seneschal reviews important dimensions of the pathogenesis of vitiligo that necessitate maintenance therapy.
The AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.
The content of the 2025 AAD Annual Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Annual Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.
